Buy & Sell Cytokinetics Inc (CYTK) – Cytokinetics Inc Price Today
Aura AI Summary
Key Stats
- $10.30BMarket Cap
- TechnologySector
- -15.01%3M Drawdown
- $10.77BEnterprise Value
- -Dividend Yield
- 7 daysTypical Hold Time
Cytokinetics Inc (CYTK) is currently valued at a market capitalization of $10.30B, with an enterprise value of $10.77B. Over the past 52 weeks, Cytokinetics Inc has traded between a low of $30.28 and a high of $78.64, highlighting its annual price range. Over the past three months, Cytokinetics Inc has recorded a drawdown of -15.01%, reflecting recent price volatility. On average, investors hold Cytokinetics Inc for approximately 7 days, indicating typical investor behavior on the platform.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Most Recent News
BlackRock's stake in Fagron briefly rises above 3% before dropping below again.
BlackRock, Inc. disclosed two transparency notifications regarding its holdings in Fagron NV. On May 11, 2026, BlackRock's stake in Fagron rose above the 3% threshold, holding 3.01% of voting rights with 2,072,188 shares plus 145,030 financial instru...

Brodsky & Smith investigates fiduciary duty breaches in merger deals of Dominion Energy, Global Business Travel, Webster Financial, and TopBuild.
Brodsky & Smith LLC has announced investigations into whether the boards of Dominion Energy, Global Business Travel Group, Webster Financial, and TopBuild breached their fiduciary duties to shareholders during recent merger agreements. These probes f...

Japanese partner urges caution on Tavneos use amid safety concerns and FDA scrutiny.
Kissei Pharmaceutical, Amgen's Japanese partner, has advised doctors to exercise caution when prescribing Tavneos (avacopan) due to safety concerns, including risks of liver dysfunction. This follows FDA warnings and a proposed withdrawal of Tavneos ...
